Biotechnology in Cuba through the glass of the CIGB scientific output: a bibliometric approach
Keywords:
bibliometrics, national scientific output, genetic engineering and biotechnology, scholarly journals, scientific rankings, Cuba.Abstract
Biotechnology has a strategic weight in the Cuban scientific output. In this context, the Center for Genetic Engineering and Biotechnology (CIGB) plays a fundamental role as the most productive scientific institute of the main Caribbean Island. In this work, the scientific production of this institution was assessed for the first time with an exhaustive bibliometric approach. A full bibliographic record was established, covering the period 1981-2022. Documentary analysis was applied, retrieving its editorial production, records in nine bibliographic databases and author profile pages at ResearchGate and ORCID. Foundational publishing milestones were addressed. Publishing dynamics alone and together with patent applications were studied, as well as its main properties and evolution. A total of 3667 institutional documents were studied, 66.6% of them indexed in mainstream databases, with an H index of 74. Institutional authors led the 69.45% of papers. The study confirmed CIGB as the top Cuban research institution attending to the number of works covered by Web of Science Core Collection and Scopus, only preceded by major universities. This center contributes 3.64-4.63% of national output in mainstream databases, 4.54-7.21% of cited documents and 6.09-8.10% of citations received by the Cuban output. After a continuous growing period, the output remained steady since the foundation of the Cuban Biotechnological and Pharmaceutical Industry (BioCubaFarma) in 2012, particularly in foreign indexed journals, and it was boosted since 2020 by the covid-19/sars-cov-2 pandemics. An updated ranking of Cuban institutions was also included, with CIGB in the top five ranking position.
References
1. Arencibia Jorge R, Corera Álvarez E, Chinchilla Rodríguez Z, de Moya Anegón F. Intersectoral relationships, scientific output and national policies for research development: A case study on Cuba 2003-2007. Revista Cubana de Información en Ciencias de la Salud. 2013 [access 17/05/23];24:243-54. Available at: http://scielo.sld.cu/pdf/ics/v24n3/rci03313.pdf.
2. Gulbrandsen M. Research institutes as hybrid organizations: central challenges to their legitimacy. Policy Science. 2011 [access 23/05/23];44:215-30. Available at: https://link.springer.com/article/10.1007/s11077-011-9128-4.
3. Arencibia-Jorge R, Corera-Alvarez E, Chinchilla-Rodríguez Z, de Moya-Anegón F. Scientific output of the emerging Cuban biopharmaceutical industry: a scientometric approach. Scientometrics. 2016 [access 06/06/23];108(3):1621-36. Available at: https://link.springer.com/article/10.1007/s11192-016-2023-1
4. Borroto Leal O, Borroto Nordelo C, Cornide Hernández MT, Díaz Otero S, Frías Lepoureau MT, Muñiz Ugarte O, et al. Análisis de los Premios de la Academia de Ciencias de Cuba sección Ciencias Agrarias y de la Pesca (1996-2010). Anales de la Academia de Ciencias de Cuba. 2011 [access 16/06/23];11(1):1-30. Available at: https://revistaccuba.sld.cu/index.php/revacc/article/view/4/4.
5. Araujo-Ruíz JA, Arencibia-Jorge R, Vega-Almeida RL, Sánchez-Tarragó N. Producción científica cubana sobre Dengue en el contexto internacional (Scopus, 1981-2006). Revista CENIC. Ciencias Biológicas. 2010 [access 11/06/23];41(Especial):1-11. Available at: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352008000900005
6. Araujo-Ruiz JA, Van Hooydonk G, Torricella-Morales RG, Arencibia-Jorge R. Cuban scientific articles in ISI Citation Indexes and CubaCiencias databases (1988-2003). Scientometrics. 2005;65(2):161-71.
7. Arencibia-Jorge R, Araujo Ruíz JA, Hung Llamos BR, Chinchilla Rodríguez Z, Alemán Zeledón FS, Hernández Cañadas P, et al. Bibliometric study of Latin American countries supported by INASP 1996-2008. Project Report. Oxford: INASP, 2011.
8. Cañedo Andalia R, Guzmán Sánchez MV, Rodríguez Labrada R. Cuban Document Scientific Production Registered in Scopus and PubMed in the Period 2001-2010. Correo Científico Médico. 2012 [access 14/06/2022];16(1). Available at: https://revcocmed.sld.cu/index.php/cocmed/article/view/238.
9. Cañedo Andalia R, Rodríguez Labrada R, Velázquez Pérez L. Cuban health scientific production registered in Scopus and PubMed in 2011. breakdown by source institution. Revista Cubana de Información en Ciencias de la Salud. 2013 [access 14/06/2022];24(1):3-22. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2307-21132013000100002
10. Monge-Nájera J, Olivera Batista D, Ho YS. Cuba Publications in the Science Citation Index Expanded: publication characteristics, institutions and journals. Revista de Biología Tropical. 2021;69(3):1098-106. DOI: http://dx.doi.org/10.15517/rbt.v69i3.46976
11. Palacios-Callender M, Roberts SA, Roth-Berghofer T. Evaluating patterns of national and international collaboration in Cuban Science using bibliometric tools. Journal of Documentation. 2016;72(2):362-90.
12. Campos Jiménez E, Campos Ferrer A. Biotechnological overview of Latin America from the perspective of immunological patents. Revista Cubana de Información en Ciencias de la Salud. 2014 [access 14/06/2022];25(2):172-82. Available at: http://scielo.sld.cu/scielo.php?pid=S2307-21132014000200004&script=sci_abstract&tlng=en
13. Díaz Pérez M, Giráldez Reyes R, Carrillo-Calvet HA. Metric behavior of patents granted in Cuba: Its contribution to the national technological innovation. Investigación Bibliotecológica. 2017; (Special Issue):271-89. DOI: https://doi.org/10.22201/iibi.24488321xe.2017.nesp1.57893
14. Guzmán-Sánchez MV, Piñón-Lora M, Villaseñor-García EA, Jiménez-Andrade JL, Carrillo-Calvet H. Characterization of the Cuban biopharmaceutical industry from collaborative networks. Scientometrics. 2018;115(3):1533-48. DOI: http://dx.doi.org/10.1007/s11192-018-2719-5
15. Guzmán-Sánchez MV, Piñón M, Jiménez-Andrade JL, Villaseñor EA, Carrillo-Calvet H. Characterization of the Cuban biopharmaceutical industry from collaborative networks. Paper presented at the Info'2016, La Habana; 2016.
16. Arencibia Jorge R, Vega Almeida RL, Araújo Ruiz JA, Corera Álvarez E, de Moya Anegón F. Milestones of the Cuban Science in the XXI Century, a review of the most cited papers in Scopus, 2001-2005. Acimed. 2012 [access 14/06/2022];23(1):45-58. Available at http://scielo.sld.cu/pdf/aci/v23n1/aci05112.pdf
17. Arencibia Jorge R, Vega Almeida RL, Araújo Ruiz JA, Corera Álvarez E, de Moya Anegón F. Milestones of the Cuban Science in the XXI century, a review of the most cited papers in Scopus, 2006-2010. Acimed. 2012 [access 14/06/2022];;23(2):175-86. Available at http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352012000200007
18. Hernández-Ferreras K, Cárdenas-de-Baños L, Fundora-Mirabal J, Dorta-Contreras AJ. Cuban most productive biomedicine scientists in Medline in the period 1996-2011. Acimed. 2012 [access 14/06/2022];23(4):362-79. Available at http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352012000400004
19. Olivera Batista D, Peralta González MJ, García García O. Co-authorship as expression of collaboration in the scientific production of Camagüey. Biblios. 2018;(70):423. DOI: https://doi.org/10.5195/biblios.2018.423
20. Galbán-Rodríguez E, Torres-Ponjuán D, Martí-Lahera Y, Arencibia-Jorge R. Measuring the Cuban scientific output in scholarly journals through a comprehensive coverage approach. Scientometrics. 2019;121(2):1019-43. DOI: https://doi.org/10.1007/s11192-019-03233-6
21. OECD and SCImago Research Group (CSIC). Compendium of Bibliometric Science Indicators. Paris: OECD; 2016.
22. Noyons ECM. Bibliometric mapping as a science policy and research management tool. Leiden: DSWO Press; 1999.
23. Nuñez Gudas N. Pedro Antonio López Saura (1947-2016). 2022 [access 14/06/2022]. Available at: http://articulos.sld.cu/editorhome/2016/09/05/pedro-antonio-lopez-saura-1947-2016/
24. ResearchGate. Center for Genetic Engineering and Biotechnology. 2022 [access 14/06/2022]. Available at: https://www.researchgate.net/institution/Center_for_Genetic_Engineering_and_Biotechnology/members.
25. Biblioteca Nacional José Martí, Ministerio de Cultura. B
26. Ministerio de Cultura. Agencia Cubana del ISBN. 2022 [access 14/06/2022]. Available at: www.isbncuba.cult.cu.
27. Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-38. DOI: https://doi.org/10.1007/s11192-009-0146-3
28. Galbán-Rodríguez E. Estudio multidimensional de la revista Biotecnología Aplicada, 1984-2012. (Thesis, MSc.). Havana University: La Habana; 2016.
29. Haak LL, Fenner M, Paglione L, Pentz E, Ratner H. ORCID: A system to uniquely identify researchers. Learned Publishing. 2012;25(4):259-64. DOI: https://doi.org/10.1087/20120404
30. Abdulhayoglu MA, Thijs B. Use of ResearchGate and Google CSE for author name disambiguation. Scientometrics. 2017;111(3):1965-85. DOI: http://dx.doi.org/10.1007/s11192-017-2341-y
31. Pereira DAA, Riberiro-Neto B, Ziviani N, Laender AHF, Goncalves MA, Ferreira AA. Using web information for author name disambiguation. Paper presented at the JCDL, Austin, Texas; 2009 [access 14/06/2022]. Available at: https://dl.acm.org/doi/10.1145/1555400.1555409
32. French RB, Fagan JC. The visibility of authority records, researcher identifiers, academic social networking profiles, and related faculty publications in search engine results. Libraries. DOI: 2019;148. http://dx.doi.org/10.1080/19322909.2019.1591324
33. Bravo EM. Interferon: Pedro López Saura and Luis Herrera Martínez. In: Bravo EM (Ed.). Development within underdevelopment? New trends in Cuban Medicine. La Habana: Editorial José Martí, Elfos Scientiae; 1998. p. 51-79.
34. Barcelona S. Inaugurado oficialmente el Centro de Ingeniería Genética y Biotecnología de Cuba. Interferón y Biotecnología. 1986;3(3):247-55.
35. Limonta M. Desarrollo de la Biotecnología en Cuba. Interferón como modelo. In: Instituto de Cooperación Iberoamericana (Ed.). II Seminario Cubano sobre Interferón y I Seminario Cubano sobre Biotecnología. Vol. I. La Habana: Instituto de Cooperación Iberoamericana; 1986. p. 31-46.
36. Limonta M. Historia exitosa de una visión de futuro: La biotecnología médica en Cuba. 2012 [access 14/06/2022]. Available at: https://www.paho.org/cub/dmdocuments/BIOLimontaM.pdf.
37. Limonta M. Application of Human Leucocyte Interferon during an epidemia of Dengue hemorragic virus in Cuba. Paper presented at the II Annual International Congress for Interferon Research, San Francisco; 1981.
38. Panem S. Interferon emerging as hormone-like substance. Journal of the American Medical Association. 1982;247(4):418-21.
39. Limonta M, Ramírez V, López-Saura P, Aguilera A, Pentón-Arias E, Barcelona S, et al. Use of leukocyte interferon during an epidemic outbreak of hemorrhagic dengue (Type II) in Cuba. Interferón y Biotecnología. 1984;1(3):15-22.
40. Limonta M. Local application of Leucocyte Interferon in Hemorragic conjunctivitis. Paper presented at the III Annual International Congress for Interferon Research, Miami; 1982.
41. Instituto de Cooperación Iberoamericana. I Seminario Cubano sobre Interferón. La Habana: Instituto de Cooperación Iberoamericana; 1984.
42. Limonta M. Present state of investigations with the use of interferon in laryngeal papillomatosis in Cuba and other countries. Revista Cubana de Investigaciones Biomédicas. 1983;2(1):35-8.
43. Bravo EM. Epidermal growth factor (EGF): Carlos Mella Lizama. In: Bravo EM (Ed.). Development within underdevelopment? New trends in Cuban Medicine. La Habana: Editorial José Martí, Elfos Scientiae; 1998. p. 81-8.
44. Bringas Pérez R, Pérez Talavera S. CIBSOFT: a package of programs for the analysis of nucleic acids and proteins. Interferón y Biotecnología. 1986;3(3):225-8.
45. Instituto de Cooperación Iberoamericana. II Seminario Cubano sobre Interferón y I Seminario Cubano sobre Biotecnología. La Habana: Instituto de Cooperación Iberoamericana; 1986.
46. Griego AG, Mejides R, Machado F, Ballester M, Limonta M. Alpha-leukocyte interferon in treatment of seropositives for HIV-Longitudinal study. Journal of Interferon Research. 1987;7(6):792.
47. Thorsteinsdóttir H, Sáenz TW, Quach U, Daar AS, Singer PA. Cuba – Innovation through synergy. Nature Biotechnology. 2004;22:DC19-DC24. DOI: https://doi.org/10.1038/nbt1204supp-dc19
48. Arencibia-Jorge R, García-García L, Galbán-Rodríguez E, Carrillo-Calvet H. The multidisciplinary nature of COVID-19 research. Iberoamerican Journal of Science Measurement and Communication. 2020;1(1):003. DOI: https://doi.org/10.47909/ijsmc.13
49. Limonta M, Padrón G. The development of high technology and its medical applications in Cuba. Latin American Perspectives. 1991;18(2):101-13.
50. Gálvez Taupier LO, Abril González A. Impact of conversion of applied research centers in enterprises. An Acad Cienc Cuba. 2016 [access 14/06/2022];6(2):1-8. Available at: file:///C:/Users/hp/Downloads/343-343-1-PB.pdf
51. López Mola E, Silva Rodríguez R, Acevedo Castro BE, Acosta Buxado JA, Aguilera Rodríguez A, Herrera-Martínez LS. Biotechnology in Cuba: 20 years of scientific, social and economic progress. Journal of Commercial Biotechnology. 2006;13:1-11. DOI: http://dx.doi.org/10.1057/palgrave.jcb.3050038
52. Galbán-Rodríguez E, Torres Ponjuán D, Arencibia Jorge R. Multidimensional quantitative analysis of the Cuban scientific output and its regional context. Scientometrics. 2021;126(3):2643-65. DOI: https://doi.org/10.1007/s11192-021-03904-3
53. Dutrénit G, Núñez Jover J. Vinculación universidad-sector productivo para fortalecer los sistemas nacionales de innovación: experiencias de Cuba, México y Costa Rica. La Habana: Editorial UH; 2017.
54. Núñez Jover J, Montalvo Arriete LF. Science, Technology, and Innovation Policies and the Innovation System in Cuba: Assessment and Prospects. In: Brundenius C, Torres Pérez R (Eds.). No more free lunch: Reflections on the Cuban economic reform process and challenges for transformation. Dordrecht: Springer International Publishing; 2014; p. 153-72.
55. Núñez Jover J, Pérez Ones I, Montalvo Arriete LF. Biotechnology, University and Scientific and Technological Policy in Cuba: A look at progress and challenges. In: Göransson B, Pålsson CM (Eds.). Biotechnology and innovation systems. The role of public policy. Cheltenham: International Development Research Centre, Edward Elgar Publishing Limited; 2011. p. 80-117.
56. Scimago. Scimago Institutional Rank. 2022 [access 14/06/2022]. Available at: https://www.scimagoir.com/rankings.php.
57. Echevarría Gómez MC, Fuentes Chaviano P, Valle Fasco MG, Díaz Pérez L, García Francisco ZC. Study preliminary on university integration in the county of Sancti Spíritus. Gaceta Médica Espirituana. 2014 [access 14/06/2022];16(3). Available at: https://revgmespirituana.sld.cu/index.php/gme/article/view/581.
58. Galbán-Rodríguez E, Torres-Ponjuán D, Arencibia-Jorge R. A Journal cross-classification system to mapping Cuban scientific output. Bibliotecas. Anales de Investigación. 2021 [access 14/06/2022];;17(3):1-43. Available at: file:///C:/Users/hp/Downloads/Dialnet-UnSistemaDeClasificacionCruzadaDeRevistasParaElMap-8320404-1.pdf
59. Arencibia-Jorge R. Visibilidad internacional de la Ciencia y Educación Superior cubanas: desafíos del estudio de la producción científica. Universidad de Granada. Universidad de La Habana: Granada; 2010.
60. Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, et al. The time to offer treatments for COVID-19. Expert Opin Investig Drugs. 2021;30(5):505-18. DOI: https://doi.org/10.1080/13543784.2021.1901883
61. Anasagasti-Angulo L, García-Vega Y, Collazo S, Jiménez-Barban Y, Tijerino-Arrieta E, Ballester-Caballero Y, et al. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. Australasian Medical Journal. 2017;10(6):509-15. DOI: http://dx.doi.org/10.21767/AMJ.2017.3013
62. Colectivo de autores. Infiltración del Heberprot-P. Un tratamiento eficaz para la úlcera del pie diabético. La Habana: Elfos Scientiae; 2014.
63. Berlanga-Acosta JA, Savigne W, Valdez C, Franco N, Alba JS, Rio AD, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. International Wound Journal. 2006;3(3):232-9. DOI: https://doi.org/10.1111/j.1742-481x.2006.00237.x
64. Berlanga-Acosta JA, Abreu-Cruz A, García-del Barco Herrera D, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, et al. Synthetic growth hormone-releasing peptides (GHRPS): A historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558. DOI: https://doi.org/10.1177/1179546817694558
65. Penichet M, Rodriguez M, Castellano O, Mandado S, Rojas Y, Rubiera R, et al. Detection of Bm86 Antigen in Different Strains of Boophilus-Microplus and Effectiveness of Immunization with Recombinant Bm86. Parasite Immunology. 1994;16(9):493-500. DOI: https://doi.org/10.1111/j.1365-3024.1994.tb00377.x
66. Rodríguez Mallon A, González-López LJ, Encinosa Guzmán PE, Estrada-García MP, Bello Soto Y, Cabrales A, et al. The chemical conjugate pP0-Bm86 as an antigen of a broad-spectrum vaccine against ticks. Anales de la Academia de Ciencias de Cuba. 2022 [access 14/06/2022]; 12(2). Available at: http://www.revistaccuba.cu/index.php/revacc/article/.
67. Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). EClinicalMedicine. 2022;101383. DOI: https://doi.org/10.1016/j.eclinm.2022.101383
68. Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, et al. Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study. The Lancet Regional Health-Americas. 2022;16:100366. DOI: https://doi.org/10.1016/j.lana.2022.100366
69. Ávalos I, Lao T, Rodríguez EM, Zamora Y, Rodríguez A, Ramón A, et al. Chimeric antigen by the fusion of SARS-CoV-2 receptor binding domain with the extracellular domain of human CD154: A promising improved vaccine candidate. Vaccines. 2022;10:897. DOI: https://doi.org/10.3390/vaccines10060897
70. Valdés-Véliz R, Černigoj U, Sánchez E, Hernández D, Nemec B, Limonta M, et al. Hepatitis B Surface Antigen Particle Purification by Immunoaffinity Chromatography Based on CDI-CB.Hep-1 mAb Monolithic Supports. Bioprocessing Journal. 2018;17(1-10):1-10. DOI: http://dx.doi.org/10.12665/J17OA.Valdes
2. Gulbrandsen M. Research institutes as hybrid organizations: central challenges to their legitimacy. Policy Science. 2011 [access 23/05/23];44:215-30. Available at: https://link.springer.com/article/10.1007/s11077-011-9128-4.
3. Arencibia-Jorge R, Corera-Alvarez E, Chinchilla-Rodríguez Z, de Moya-Anegón F. Scientific output of the emerging Cuban biopharmaceutical industry: a scientometric approach. Scientometrics. 2016 [access 06/06/23];108(3):1621-36. Available at: https://link.springer.com/article/10.1007/s11192-016-2023-1
4. Borroto Leal O, Borroto Nordelo C, Cornide Hernández MT, Díaz Otero S, Frías Lepoureau MT, Muñiz Ugarte O, et al. Análisis de los Premios de la Academia de Ciencias de Cuba sección Ciencias Agrarias y de la Pesca (1996-2010). Anales de la Academia de Ciencias de Cuba. 2011 [access 16/06/23];11(1):1-30. Available at: https://revistaccuba.sld.cu/index.php/revacc/article/view/4/4.
5. Araujo-Ruíz JA, Arencibia-Jorge R, Vega-Almeida RL, Sánchez-Tarragó N. Producción científica cubana sobre Dengue en el contexto internacional (Scopus, 1981-2006). Revista CENIC. Ciencias Biológicas. 2010 [access 11/06/23];41(Especial):1-11. Available at: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352008000900005
6. Araujo-Ruiz JA, Van Hooydonk G, Torricella-Morales RG, Arencibia-Jorge R. Cuban scientific articles in ISI Citation Indexes and CubaCiencias databases (1988-2003). Scientometrics. 2005;65(2):161-71.
7. Arencibia-Jorge R, Araujo Ruíz JA, Hung Llamos BR, Chinchilla Rodríguez Z, Alemán Zeledón FS, Hernández Cañadas P, et al. Bibliometric study of Latin American countries supported by INASP 1996-2008. Project Report. Oxford: INASP, 2011.
8. Cañedo Andalia R, Guzmán Sánchez MV, Rodríguez Labrada R. Cuban Document Scientific Production Registered in Scopus and PubMed in the Period 2001-2010. Correo Científico Médico. 2012 [access 14/06/2022];16(1). Available at: https://revcocmed.sld.cu/index.php/cocmed/article/view/238.
9. Cañedo Andalia R, Rodríguez Labrada R, Velázquez Pérez L. Cuban health scientific production registered in Scopus and PubMed in 2011. breakdown by source institution. Revista Cubana de Información en Ciencias de la Salud. 2013 [access 14/06/2022];24(1):3-22. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S2307-21132013000100002
10. Monge-Nájera J, Olivera Batista D, Ho YS. Cuba Publications in the Science Citation Index Expanded: publication characteristics, institutions and journals. Revista de Biología Tropical. 2021;69(3):1098-106. DOI: http://dx.doi.org/10.15517/rbt.v69i3.46976
11. Palacios-Callender M, Roberts SA, Roth-Berghofer T. Evaluating patterns of national and international collaboration in Cuban Science using bibliometric tools. Journal of Documentation. 2016;72(2):362-90.
12. Campos Jiménez E, Campos Ferrer A. Biotechnological overview of Latin America from the perspective of immunological patents. Revista Cubana de Información en Ciencias de la Salud. 2014 [access 14/06/2022];25(2):172-82. Available at: http://scielo.sld.cu/scielo.php?pid=S2307-21132014000200004&script=sci_abstract&tlng=en
13. Díaz Pérez M, Giráldez Reyes R, Carrillo-Calvet HA. Metric behavior of patents granted in Cuba: Its contribution to the national technological innovation. Investigación Bibliotecológica. 2017; (Special Issue):271-89. DOI: https://doi.org/10.22201/iibi.24488321xe.2017.nesp1.57893
14. Guzmán-Sánchez MV, Piñón-Lora M, Villaseñor-García EA, Jiménez-Andrade JL, Carrillo-Calvet H. Characterization of the Cuban biopharmaceutical industry from collaborative networks. Scientometrics. 2018;115(3):1533-48. DOI: http://dx.doi.org/10.1007/s11192-018-2719-5
15. Guzmán-Sánchez MV, Piñón M, Jiménez-Andrade JL, Villaseñor EA, Carrillo-Calvet H. Characterization of the Cuban biopharmaceutical industry from collaborative networks. Paper presented at the Info'2016, La Habana; 2016.
16. Arencibia Jorge R, Vega Almeida RL, Araújo Ruiz JA, Corera Álvarez E, de Moya Anegón F. Milestones of the Cuban Science in the XXI Century, a review of the most cited papers in Scopus, 2001-2005. Acimed. 2012 [access 14/06/2022];23(1):45-58. Available at http://scielo.sld.cu/pdf/aci/v23n1/aci05112.pdf
17. Arencibia Jorge R, Vega Almeida RL, Araújo Ruiz JA, Corera Álvarez E, de Moya Anegón F. Milestones of the Cuban Science in the XXI century, a review of the most cited papers in Scopus, 2006-2010. Acimed. 2012 [access 14/06/2022];;23(2):175-86. Available at http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352012000200007
18. Hernández-Ferreras K, Cárdenas-de-Baños L, Fundora-Mirabal J, Dorta-Contreras AJ. Cuban most productive biomedicine scientists in Medline in the period 1996-2011. Acimed. 2012 [access 14/06/2022];23(4):362-79. Available at http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1024-94352012000400004
19. Olivera Batista D, Peralta González MJ, García García O. Co-authorship as expression of collaboration in the scientific production of Camagüey. Biblios. 2018;(70):423. DOI: https://doi.org/10.5195/biblios.2018.423
20. Galbán-Rodríguez E, Torres-Ponjuán D, Martí-Lahera Y, Arencibia-Jorge R. Measuring the Cuban scientific output in scholarly journals through a comprehensive coverage approach. Scientometrics. 2019;121(2):1019-43. DOI: https://doi.org/10.1007/s11192-019-03233-6
21. OECD and SCImago Research Group (CSIC). Compendium of Bibliometric Science Indicators. Paris: OECD; 2016.
22. Noyons ECM. Bibliometric mapping as a science policy and research management tool. Leiden: DSWO Press; 1999.
23. Nuñez Gudas N. Pedro Antonio López Saura (1947-2016). 2022 [access 14/06/2022]. Available at: http://articulos.sld.cu/editorhome/2016/09/05/pedro-antonio-lopez-saura-1947-2016/
24. ResearchGate. Center for Genetic Engineering and Biotechnology. 2022 [access 14/06/2022]. Available at: https://www.researchgate.net/institution/Center_for_Genetic_Engineering_and_Biotechnology/members.
25. Biblioteca Nacional José Martí, Ministerio de Cultura. B
26. Ministerio de Cultura. Agencia Cubana del ISBN. 2022 [access 14/06/2022]. Available at: www.isbncuba.cult.cu.
27. Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-38. DOI: https://doi.org/10.1007/s11192-009-0146-3
28. Galbán-Rodríguez E. Estudio multidimensional de la revista Biotecnología Aplicada, 1984-2012. (Thesis, MSc.). Havana University: La Habana; 2016.
29. Haak LL, Fenner M, Paglione L, Pentz E, Ratner H. ORCID: A system to uniquely identify researchers. Learned Publishing. 2012;25(4):259-64. DOI: https://doi.org/10.1087/20120404
30. Abdulhayoglu MA, Thijs B. Use of ResearchGate and Google CSE for author name disambiguation. Scientometrics. 2017;111(3):1965-85. DOI: http://dx.doi.org/10.1007/s11192-017-2341-y
31. Pereira DAA, Riberiro-Neto B, Ziviani N, Laender AHF, Goncalves MA, Ferreira AA. Using web information for author name disambiguation. Paper presented at the JCDL, Austin, Texas; 2009 [access 14/06/2022]. Available at: https://dl.acm.org/doi/10.1145/1555400.1555409
32. French RB, Fagan JC. The visibility of authority records, researcher identifiers, academic social networking profiles, and related faculty publications in search engine results. Libraries. DOI: 2019;148. http://dx.doi.org/10.1080/19322909.2019.1591324
33. Bravo EM. Interferon: Pedro López Saura and Luis Herrera Martínez. In: Bravo EM (Ed.). Development within underdevelopment? New trends in Cuban Medicine. La Habana: Editorial José Martí, Elfos Scientiae; 1998. p. 51-79.
34. Barcelona S. Inaugurado oficialmente el Centro de Ingeniería Genética y Biotecnología de Cuba. Interferón y Biotecnología. 1986;3(3):247-55.
35. Limonta M. Desarrollo de la Biotecnología en Cuba. Interferón como modelo. In: Instituto de Cooperación Iberoamericana (Ed.). II Seminario Cubano sobre Interferón y I Seminario Cubano sobre Biotecnología. Vol. I. La Habana: Instituto de Cooperación Iberoamericana; 1986. p. 31-46.
36. Limonta M. Historia exitosa de una visión de futuro: La biotecnología médica en Cuba. 2012 [access 14/06/2022]. Available at: https://www.paho.org/cub/dmdocuments/BIOLimontaM.pdf.
37. Limonta M. Application of Human Leucocyte Interferon during an epidemia of Dengue hemorragic virus in Cuba. Paper presented at the II Annual International Congress for Interferon Research, San Francisco; 1981.
38. Panem S. Interferon emerging as hormone-like substance. Journal of the American Medical Association. 1982;247(4):418-21.
39. Limonta M, Ramírez V, López-Saura P, Aguilera A, Pentón-Arias E, Barcelona S, et al. Use of leukocyte interferon during an epidemic outbreak of hemorrhagic dengue (Type II) in Cuba. Interferón y Biotecnología. 1984;1(3):15-22.
40. Limonta M. Local application of Leucocyte Interferon in Hemorragic conjunctivitis. Paper presented at the III Annual International Congress for Interferon Research, Miami; 1982.
41. Instituto de Cooperación Iberoamericana. I Seminario Cubano sobre Interferón. La Habana: Instituto de Cooperación Iberoamericana; 1984.
42. Limonta M. Present state of investigations with the use of interferon in laryngeal papillomatosis in Cuba and other countries. Revista Cubana de Investigaciones Biomédicas. 1983;2(1):35-8.
43. Bravo EM. Epidermal growth factor (EGF): Carlos Mella Lizama. In: Bravo EM (Ed.). Development within underdevelopment? New trends in Cuban Medicine. La Habana: Editorial José Martí, Elfos Scientiae; 1998. p. 81-8.
44. Bringas Pérez R, Pérez Talavera S. CIBSOFT: a package of programs for the analysis of nucleic acids and proteins. Interferón y Biotecnología. 1986;3(3):225-8.
45. Instituto de Cooperación Iberoamericana. II Seminario Cubano sobre Interferón y I Seminario Cubano sobre Biotecnología. La Habana: Instituto de Cooperación Iberoamericana; 1986.
46. Griego AG, Mejides R, Machado F, Ballester M, Limonta M. Alpha-leukocyte interferon in treatment of seropositives for HIV-Longitudinal study. Journal of Interferon Research. 1987;7(6):792.
47. Thorsteinsdóttir H, Sáenz TW, Quach U, Daar AS, Singer PA. Cuba – Innovation through synergy. Nature Biotechnology. 2004;22:DC19-DC24. DOI: https://doi.org/10.1038/nbt1204supp-dc19
48. Arencibia-Jorge R, García-García L, Galbán-Rodríguez E, Carrillo-Calvet H. The multidisciplinary nature of COVID-19 research. Iberoamerican Journal of Science Measurement and Communication. 2020;1(1):003. DOI: https://doi.org/10.47909/ijsmc.13
49. Limonta M, Padrón G. The development of high technology and its medical applications in Cuba. Latin American Perspectives. 1991;18(2):101-13.
50. Gálvez Taupier LO, Abril González A. Impact of conversion of applied research centers in enterprises. An Acad Cienc Cuba. 2016 [access 14/06/2022];6(2):1-8. Available at: file:///C:/Users/hp/Downloads/343-343-1-PB.pdf
51. López Mola E, Silva Rodríguez R, Acevedo Castro BE, Acosta Buxado JA, Aguilera Rodríguez A, Herrera-Martínez LS. Biotechnology in Cuba: 20 years of scientific, social and economic progress. Journal of Commercial Biotechnology. 2006;13:1-11. DOI: http://dx.doi.org/10.1057/palgrave.jcb.3050038
52. Galbán-Rodríguez E, Torres Ponjuán D, Arencibia Jorge R. Multidimensional quantitative analysis of the Cuban scientific output and its regional context. Scientometrics. 2021;126(3):2643-65. DOI: https://doi.org/10.1007/s11192-021-03904-3
53. Dutrénit G, Núñez Jover J. Vinculación universidad-sector productivo para fortalecer los sistemas nacionales de innovación: experiencias de Cuba, México y Costa Rica. La Habana: Editorial UH; 2017.
54. Núñez Jover J, Montalvo Arriete LF. Science, Technology, and Innovation Policies and the Innovation System in Cuba: Assessment and Prospects. In: Brundenius C, Torres Pérez R (Eds.). No more free lunch: Reflections on the Cuban economic reform process and challenges for transformation. Dordrecht: Springer International Publishing; 2014; p. 153-72.
55. Núñez Jover J, Pérez Ones I, Montalvo Arriete LF. Biotechnology, University and Scientific and Technological Policy in Cuba: A look at progress and challenges. In: Göransson B, Pålsson CM (Eds.). Biotechnology and innovation systems. The role of public policy. Cheltenham: International Development Research Centre, Edward Elgar Publishing Limited; 2011. p. 80-117.
56. Scimago. Scimago Institutional Rank. 2022 [access 14/06/2022]. Available at: https://www.scimagoir.com/rankings.php.
57. Echevarría Gómez MC, Fuentes Chaviano P, Valle Fasco MG, Díaz Pérez L, García Francisco ZC. Study preliminary on university integration in the county of Sancti Spíritus. Gaceta Médica Espirituana. 2014 [access 14/06/2022];16(3). Available at: https://revgmespirituana.sld.cu/index.php/gme/article/view/581.
58. Galbán-Rodríguez E, Torres-Ponjuán D, Arencibia-Jorge R. A Journal cross-classification system to mapping Cuban scientific output. Bibliotecas. Anales de Investigación. 2021 [access 14/06/2022];;17(3):1-43. Available at: file:///C:/Users/hp/Downloads/Dialnet-UnSistemaDeClasificacionCruzadaDeRevistasParaElMap-8320404-1.pdf
59. Arencibia-Jorge R. Visibilidad internacional de la Ciencia y Educación Superior cubanas: desafíos del estudio de la producción científica. Universidad de Granada. Universidad de La Habana: Granada; 2010.
60. Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, et al. The time to offer treatments for COVID-19. Expert Opin Investig Drugs. 2021;30(5):505-18. DOI: https://doi.org/10.1080/13543784.2021.1901883
61. Anasagasti-Angulo L, García-Vega Y, Collazo S, Jiménez-Barban Y, Tijerino-Arrieta E, Ballester-Caballero Y, et al. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. Australasian Medical Journal. 2017;10(6):509-15. DOI: http://dx.doi.org/10.21767/AMJ.2017.3013
62. Colectivo de autores. Infiltración del Heberprot-P. Un tratamiento eficaz para la úlcera del pie diabético. La Habana: Elfos Scientiae; 2014.
63. Berlanga-Acosta JA, Savigne W, Valdez C, Franco N, Alba JS, Rio AD, et al. Epidermal growth factor intralesional infiltrations can prevent amputation in patients with advanced diabetic foot wounds. International Wound Journal. 2006;3(3):232-9. DOI: https://doi.org/10.1111/j.1742-481x.2006.00237.x
64. Berlanga-Acosta JA, Abreu-Cruz A, García-del Barco Herrera D, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, et al. Synthetic growth hormone-releasing peptides (GHRPS): A historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558. DOI: https://doi.org/10.1177/1179546817694558
65. Penichet M, Rodriguez M, Castellano O, Mandado S, Rojas Y, Rubiera R, et al. Detection of Bm86 Antigen in Different Strains of Boophilus-Microplus and Effectiveness of Immunization with Recombinant Bm86. Parasite Immunology. 1994;16(9):493-500. DOI: https://doi.org/10.1111/j.1365-3024.1994.tb00377.x
66. Rodríguez Mallon A, González-López LJ, Encinosa Guzmán PE, Estrada-García MP, Bello Soto Y, Cabrales A, et al. The chemical conjugate pP0-Bm86 as an antigen of a broad-spectrum vaccine against ticks. Anales de la Academia de Ciencias de Cuba. 2022 [access 14/06/2022]; 12(2). Available at: http://www.revistaccuba.cu/index.php/revacc/article/.
67. Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, et al. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). EClinicalMedicine. 2022;101383. DOI: https://doi.org/10.1016/j.eclinm.2022.101383
68. Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, et al. Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study. The Lancet Regional Health-Americas. 2022;16:100366. DOI: https://doi.org/10.1016/j.lana.2022.100366
69. Ávalos I, Lao T, Rodríguez EM, Zamora Y, Rodríguez A, Ramón A, et al. Chimeric antigen by the fusion of SARS-CoV-2 receptor binding domain with the extracellular domain of human CD154: A promising improved vaccine candidate. Vaccines. 2022;10:897. DOI: https://doi.org/10.3390/vaccines10060897
70. Valdés-Véliz R, Černigoj U, Sánchez E, Hernández D, Nemec B, Limonta M, et al. Hepatitis B Surface Antigen Particle Purification by Immunoaffinity Chromatography Based on CDI-CB.Hep-1 mAb Monolithic Supports. Bioprocessing Journal. 2018;17(1-10):1-10. DOI: http://dx.doi.org/10.12665/J17OA.Valdes
Downloads
Published
2024-11-19
How to Cite
1.
Galbán RodrÃguez E, Ramos Gómez Y, Vázquez Castillo M, Arencibia Jorge R. Biotechnology in Cuba through the glass of the CIGB scientific output: a bibliometric approach. Rev. cuba. inf. cienc. salud [Internet]. 2024 Nov. 19 [cited 2024 Dec. 25];35. Available from: https://acimed.sld.cu/index.php/acimed/article/view/2889
Issue
Section
Artículos Originales
License
Aquellos autores que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un repositorio institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores difundir su obra a través de Internet (p. ej.: en repositorios institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto). En ese caso, solicitamos que en la cabecera del manuscrito se indique:"Esta es una versión preprint enviada a la Revista Cubana de Información en Ciencias de la Salud http://rcics.sld.cu/"
ENGLISH VERSION
AUTHORS WITH PUBLICATIONS IN THIS JOURNAL ACCEPT THE FOLLOWING TERMS:
- Authors will retain their copyright and will grant the Journal the right of first publication of their work, which will also be subject to a Creative Commons License Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) allowing third parties to share the work as long as the author's name and data about initial publication in this Journal are stated.
- Authors may adopt other license agreements for non-exclusive distribution of the version of the work published (e.g. deposit it in an institutional repository or publish it in a monographic volume), as long as initial publication in this Journal is indicated.
- It is permitted and recommended for authors to disseminate their work on the Internet (e.g. in institutional repositories or their web page) before and during the submission process, which may result in interesting exchanges and increase the number of citations of the published work) (see The effect of open access).
